vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $326.2M, roughly 1.8× New Fortress Energy Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -259.7%, a 300.5% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -7.0%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-134.8M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -26.8%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
EXEL vs NFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $326.2M |
| Net Profit | $244.5M | $-847.1M |
| Gross Margin | 95.6% | 35.5% |
| Operating Margin | 39.3% | -193.0% |
| Net Margin | 40.8% | -259.7% |
| Revenue YoY | 5.6% | -7.0% |
| Net Profit YoY | 74.8% | -277.4% |
| EPS (diluted) | $0.89 | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $326.2M | ||
| Q3 25 | $568.3M | $240.3M | ||
| Q2 25 | $555.4M | $228.1M | ||
| Q1 25 | $566.8M | $384.9M | ||
| Q4 24 | — | $350.7M | ||
| Q3 24 | $539.5M | $446.0M | ||
| Q2 24 | $637.2M | $291.2M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $-847.1M | ||
| Q3 25 | $184.8M | $-263.0M | ||
| Q2 25 | $159.6M | $-546.5M | ||
| Q1 25 | $139.9M | $-175.4M | ||
| Q4 24 | — | $-224.4M | ||
| Q3 24 | $118.0M | $9.3M | ||
| Q2 24 | $226.1M | $-88.9M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 35.5% | ||
| Q3 25 | 96.6% | 18.1% | ||
| Q2 25 | 96.5% | 8.4% | ||
| Q1 25 | 96.5% | 21.4% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | 96.8% | 27.1% | ||
| Q2 24 | 97.2% | 23.8% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -193.0% | ||
| Q3 25 | 37.6% | -37.4% | ||
| Q2 25 | 33.6% | -170.3% | ||
| Q1 25 | 28.8% | -3.3% | ||
| Q4 24 | — | 65.0% | ||
| Q3 24 | 25.2% | 17.8% | ||
| Q2 24 | 43.3% | 12.3% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | -259.7% | ||
| Q3 25 | 32.5% | -109.4% | ||
| Q2 25 | 28.7% | -239.6% | ||
| Q1 25 | 24.7% | -45.6% | ||
| Q4 24 | — | -64.0% | ||
| Q3 24 | 21.9% | 2.1% | ||
| Q2 24 | 35.5% | -30.5% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $-3.03 | ||
| Q3 25 | $0.65 | $-0.96 | ||
| Q2 25 | $0.55 | $-1.99 | ||
| Q1 25 | $0.47 | $-0.65 | ||
| Q4 24 | — | $-1.10 | ||
| Q3 24 | $0.40 | $0.03 | ||
| Q2 24 | $0.77 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $226.5M |
| Total DebtLower is stronger | — | $8.2B |
| Stockholders' EquityBook value | $2.2B | $182.6M |
| Total Assets | $2.8B | $10.6B |
| Debt / EquityLower = less leverage | — | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $226.5M | ||
| Q3 25 | $791.1M | $145.2M | ||
| Q2 25 | $1.0B | $551.1M | ||
| Q1 25 | $1.1B | $447.9M | ||
| Q4 24 | — | $492.9M | ||
| Q3 24 | $1.2B | $90.8M | ||
| Q2 24 | $1.0B | $133.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $182.6M | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.2B | $1.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | $2.3B | $1.6B | ||
| Q2 24 | $2.1B | $1.6B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $10.6B | ||
| Q3 25 | $2.7B | $12.0B | ||
| Q2 25 | $2.8B | $12.0B | ||
| Q1 25 | $2.9B | $13.1B | ||
| Q4 24 | — | $12.9B | ||
| Q3 24 | $3.0B | $12.0B | ||
| Q2 24 | $2.8B | $11.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-76.2M |
| Free Cash FlowOCF − Capex | $332.4M | $-134.8M |
| FCF MarginFCF / Revenue | 55.5% | -41.3% |
| Capex IntensityCapex / Revenue | 0.2% | 18.0% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-76.2M | ||
| Q3 25 | $49.0M | $-171.0M | ||
| Q2 25 | $211.4M | $-329.0M | ||
| Q1 25 | $240.3M | $-7.2M | ||
| Q4 24 | — | $445.3M | ||
| Q3 24 | $271.3M | $-20.0M | ||
| Q2 24 | $119.5M | $113.9M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-134.8M | ||
| Q3 25 | $46.2M | $-231.6M | ||
| Q2 25 | $208.5M | $-726.7M | ||
| Q1 25 | $236.3M | $-262.3M | ||
| Q4 24 | — | $-210.3M | ||
| Q3 24 | $263.1M | $-367.0M | ||
| Q2 24 | $113.0M | $-493.2M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -41.3% | ||
| Q3 25 | 8.1% | -96.4% | ||
| Q2 25 | 37.5% | -318.6% | ||
| Q1 25 | 41.7% | -68.2% | ||
| Q4 24 | — | -60.0% | ||
| Q3 24 | 48.8% | -82.3% | ||
| Q2 24 | 17.7% | -169.3% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 18.0% | ||
| Q3 25 | 0.5% | 25.2% | ||
| Q2 25 | 0.5% | 174.4% | ||
| Q1 25 | 0.7% | 66.3% | ||
| Q4 24 | — | 187.0% | ||
| Q3 24 | 1.5% | 77.8% | ||
| Q2 24 | 1.0% | 208.4% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | -2.15× | ||
| Q2 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
NFE
Segment breakdown not available.
